Authors: DiNicolantonio JJ, Barroso-Aranda J, McCarty MF PMID: 33875563 PMCID: PMC8057070 DOI: 10.1136/openhrt-2021-001655 Abstract Ivermectin, a drug commonly used to treat a range of parasitic infections, has been shown to halve the mortality elicited by a fatal dose of lipopolysaccharide in mice, in an oral dose (4 mg/kg) that can be extrapolated to 2–4 times the [...]

Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.

Authors: Ranjbar K, Shahriarad R, erfani A, Khodamoradi Z, Saadi MH PMID: 33838657 PMCID: PMC8035859 DOI: 10.1186/s12879-021-06045-3 Abstract Background: Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the [...]

INTRODUCTION: Our aim was to investigate the efficacy of vitamin C, melatonin, and zinc in patients with severe Covid-19.

Authors: Watchorn J, Hang DY, Joslin J, Bramham K, Hutchings SD PMID: 32890313 DOI: 10.1097/SHK.0000000000001659 Abstract Background: Acute kidney injury (AKI) is a common complication of COVID-19 critical illness but the pathophysiology is uncertain. Some evidence has indicated that a vascular aetiology may be implicated. We used contrast-enhanced ultrasound (CEUS) and echocardiography to study renal [...]

Authors: Doaei S, Gholami S, Rastgoo S, Bourbour F, Ghorat F, Joola P PMID: 33781275 PMCID: PMC8006115 DOI: 10.1186/s12967-021-02795-5 Abstract Background: Omega-3 polyunsaturated fatty acids (n3-PUFAs) may exert beneficial effects on the immune system of patients with viral infections. This paper aimed to examine the effect of n3-PUFA supplementation on inflammatory and biochemical markers in [...]

Authors: Janiaud P, Axfors C, Schmitt AM, Glory V, Moher D PMID: 33635310 PMCID: PMC7911095 DOI: 10.1001/jama.2021.2747 Abstract Importance: Convalescent plasma is a proposed treatment for COVID-19. Objective: To assess clinical outcomes with convalescent plasma treatment vs placebo or standard of care in peer-reviewed and preprint publications or press releases of randomized clinical trials (RCTs). [...]

Authors: Jalali F, Rezaie S, Rola P, Kyle-Sidell C doi: http://dx.doi.org/10.2139/ssrn.3800402 Abstract Established evidence suggests that in ARDS, platelets may exhibit a dysregulated state that exacerbates lung injury. We review evidence that suggests this platelet-mediated lung injury, while present in ARDS in general, is amplified in COVID-19 ARDS in particular. Driven by a quantifiably higher [...]

Authors: Zarehoseinzade E, Allami A, Ahmadi M, Bijani B PMID: 34169042 PMCID: PMC8214036 DOI: 10.47176/mjiri.35.30 Abstract Background: There is controversy about the efficacy of 5-alpha-reductase inhibitors in COVID-19 patients. Some assumed that finasteride might be a risk factor for deterioration and others proposed it as a possible adjunct treatment for moderate [...]

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID-19 medical countermeasures. Clinical data suggest that famotidine may mitigate COVID-19 disease, but both mechanism of action and rationale for dose selection remain obscure.